Learn About ImmixBio (NASDAQ:IMMX) Technology

Cancer growth is driven by a supportive inflammatory tumor micro-environment (“TME”), which provides nutritional and structural support for tumor expansion. The TME is made up of a tightly packed mass of: 1) cancer associated fibroblasts (“CAFs”), 2) tumor-associated macrophages/immune cells (“TAMs”), and 3) cancer itself. The TME’s biophysical properties include regions of varying degrees of hypoxia (low oxygen concentration), acidosis (an excessively acidic condition) and an immunosuppressive milieu.

Current cancer treatment approaches are generally either cytotoxic chemotherapies or focus on targeting one single receptor or one single mutation, which limits their ability to counter an evolvable tumor and its micro-environment.

At Immix Biopharma, our SMARxT Tissue-Specific Platform produces Tissue-Specific Therapies (TSTx), which in cancer target all 3 components of the TME simultaneously, severing the critical lifelines between the tumor and its metabolic support using TME Normalization Technology. In immuno-dysregulated diseases, our Immune Normalization Technology halts the self-sustaining feed-forward loop propagated among 3 key cell-types in inflammatory bowel disease, addressing the root cause of inflammatory pathologies. Our mission is to create an entirely new class Tissue-Specific Therapeutics (TSTx) that personalize treatment to address the complexity of diseases in every patient, starting with oncology & immuno-dysregulated diseases.